Immunome, Inc.

IMNM Healthcare Biotechnology

Immunome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.9 million, down 23.2% from fiscal 2024.

Revenue
+69.8%
EPS
−30.0%
Free cash flow
−27.0%

Quarter to June 2026, against a year earlier

18.86 0.95 +5.30%
Market cap
$2.1B
P/E
0.0×
Fwd P/E
−7.6×
Dividend yield
—
F-score
4/9
Altman Z
21.57
Beneish M
n/a
Dividend safety
n/a

Immunome, Inc. (IMNM) Operating margin

Alert me on Operating margin

Immunome, Inc.'s operating margin over the twelve months to 30 June 2026 was 0.00%, up 3228.8 percentage points from fiscal 2025 (−3,228.8%). Over the past ten years it has ranged from −3,382.4% (fiscal 2024) to 0.00% (fiscal 2022); the current reading is higher than 25% of that period. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.

Operating margin, annual

Embed this chart

Annual newest first

Period Operating margin Change (points)
FY2025 −3,228.8% 153.54
FY2024 −3,382.4% (2,601.02)
FY2023 −781.4% (781.35)
FY2022 0.00% 0.00
FY2021 0.00% 0.00
FY2020 0.00% 0.00
FY2019 0.00% 0.00
FY2018 0.00% —

Quarterly newest first

Period Operating margin Change (points)
Jun 2026 0.00% 0.00
Mar 2026 0.00% 0.00
Dec 2025 0.00% 0.00
Sep 2025 0.00% 1,157.61
23 more quarters

Against its own ten years

Low −3,382.4% High 0.00%
Ten-year median 0.00%
Current reading's percentile 25

Operating margin against peers

What Operating margin is

EBIT Margin tells an investor how much operating profit, before interest and taxes, a company keeps from each unit of revenue.

EBIT ÷ Revenue

The full definition of Operating margin →

More on IMNM